company background image
VVOS logo

Vivos Therapeutics NasdaqCM:VVOS Stock Report

Last Price

US$4.92

Market Cap

US$5.9m

7D

-0.2%

1Y

-55.3%

Updated

28 Feb, 2024

Data

Company Financials +

Vivos Therapeutics, Inc.

NasdaqCM:VVOS Stock Report

Market Cap: US$5.9m

VVOS Stock Overview

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.

VVOS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Vivos Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vivos Therapeutics
Historical stock prices
Current Share PriceUS$4.92
52 Week HighUS$48.79
52 Week LowUS$2.73
Beta8.32
1 Month Change-25.45%
3 Month Change-79.92%
1 Year Change-55.27%
3 Year Change-97.21%
5 Year Changen/a
Change since IPO-97.81%

Recent News & Updates

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Recent updates

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

May 21
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Analysts Are More Bearish Than They Used To Be

Vivos Therapeutics: First Take After The Broad Market Sell-Off

Mar 06

Vivos Therapeutics: Reimagining Sleep

Jul 30

Vivos Therapeutics prices $24M follow-on offering

May 07

Shareholder Returns

VVOSUS HealthcareUS Market
7D-0.2%-0.4%2.1%
1Y-55.3%5.7%26.0%

Return vs Industry: VVOS underperformed the US Healthcare industry which returned 6% over the past year.

Return vs Market: VVOS underperformed the US Market which returned 25.1% over the past year.

Price Volatility

Is VVOS's price volatile compared to industry and market?
VVOS volatility
VVOS Average Weekly Movement240.6%
Healthcare Industry Average Movement7.1%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: VVOS's share price has been volatile over the past 3 months.

Volatility Over Time: VVOS's weekly volatility has increased from 120% to 241% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016132R. Huntsmanhttps://vivos.com

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.

Vivos Therapeutics, Inc. Fundamentals Summary

How do Vivos Therapeutics's earnings and revenue compare to its market cap?
VVOS fundamental statistics
Market capUS$5.88m
Earnings (TTM)-US$15.41m
Revenue (TTM)US$14.50m

0.4x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VVOS income statement (TTM)
RevenueUS$14.50m
Cost of RevenueUS$5.94m
Gross ProfitUS$8.57m
Other ExpensesUS$23.98m
Earnings-US$15.41m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-12.87
Gross Margin59.06%
Net Profit Margin-106.27%
Debt/Equity Ratio0%

How did VVOS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.